Funder: National Institutes of Health
Due Dates: May 7, 2025 (AIDS) | June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | May 7, 2026 (AIDS) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | September 7, 2026 (AIDS) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | January 7, 2027 (AIDS)
Funding Amounts: Up to $499,999 direct costs per year, for a maximum project period of 5 years (R01 mechanism).
Summary: Supports investigator-initiated early phase (Phase 0, I, II) clinical trials of cancer-targeted diagnostic and therapeutic interventions relevant to NCI’s DCTD and OHAM research missions.
Key Information: Phase III trials are not supported; at least one clinical trial must be included per application; foreign and domestic applicants are eligible.